Matthias Augustin

Jun 13, 2024 | bpno.dk | Matthias Augustin

juni 2024 Professor Matthias Augustin outlines in this MEDtalk the WHO-5 questionnaire as an effective instrument for measuring patient well-being and suggests its integration into routine care to better identify and address the psychosocial burdens in psoriasis patients.

Jun 10, 2024 | bpno.dk | Matthias Augustin

juni 2024 Professor Matthias Augustin presents a study on tildrakizumab, which aimed to improve the well-being of psoriasis patients. The study was unique in measuring well-being as the primary endpoint, using the WHO-5 questionnaire alongside other quality-of-life metrics. One of the results showed that tildrakizumab significantly improves patients’ well-being in patients with moderate-to-severe plague psoriasis.

May 22, 2024 | medscape.com | Andreas Wollenberg |Matthias Augustin |Kenji Kabashima

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Atopic dermatitis (AD) is a complex disease with several systemic treatment options evaluated in the 2022 EuroGuiDerm guideline on AD and new data continuing to emerge.

Oct 8, 2023 | onlinelibrary.wiley.com | Matthias Augustin |Swen M. John

In this issue of JEADV, Gisondi et al.1 address one of the key topics in global dermatology: the disease burden from the patient's perspective. Burden was operationalized by measuring health-related quality of life (QoL) with the validated Dermatology Life Quality Index (DLQI); other constructs were assessed using non-validated single items, such as for depression, work impairment and stigmatization.